AGIO Stock Rockets After Announcing $2 Billion Oncology Sale To Servier

Daily Updates

Agios Pharmaceuticals (AGIO) will sell its oncology business to Servier for up to $2 billion, the biotech company said Monday. In response, AGIO stock skyrocketed.


Under the terms of the deal, Agios will receive $1.8 billion in cash up front. In addition, Servier will make a $200 million regulatory milestone payment for brain cancer drug, vorasidenib. Agios will also receive future royalties on U.S. net sales of leukemia drug Tibsovo and vorasidenib.

The deal frees Agios up to focus on its drug, mitapivat, in anemia treatment, and its pipeline of treatments for genetic diseases.

In premarket trading on the stock market today, AGIO stock soared 33.7% near 44.40.

More to follow.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Moderna Snags Covid Vaccine Authorization, Trailing Pfizer By A Week

Is Pfizer Stock A Buy After FDA Authorizes Its Coronavirus Vaccine?

Find The Best Long-Term Investments With IBD Long-Term Leaders

Looking For The Next Apple Or Amazon? Start With These S&P 500-Beating Lists

IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *